FORMULATION ARTICLES
-
![Human anatomy, medical, biology, science, healthcare-GettyImages-1458871453]( "The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology")
The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To NephrologyNanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.
-
![Molecular biology, mRNA strands, genetics-GettyImages-2198118160]( "Engineering Translation: How tRNA Therapeutics Expand The RNA Toolkit")
Engineering Translation: How tRNA Therapeutics Expand The RNA ToolkitEngineered tRNAs target translation itself — correcting shared errors like premature stop codons at the ribosome — to restore functional protein and redefine precision medicine by mechanism, not diagnosis.
-
![Chromosomes with Telomere floating, science, anti aging technology-GettyImages-1486563542]( "Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage")
Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA DamagePre-treatment with telomerase mRNA shields human skin from radiation-induced DNA damage, reducing radiotherapy side effects.
-
![AI medical technology-GettyImages-2233342016]( "Targeted Delivery – A Holy Grail For CRISPR Gene Editing")
Targeted Delivery – A Holy Grail For CRISPR Gene EditingPrecise CRISPR delivery remains the bottleneck to safer, more potent gene editing. Advances in LNP design, targeting strategies, and extrahepatic delivery are redefining what’s possible in vivo.
-
![Ribosome, biological cell constructing mRNA molecule-GettyImages-1352440366]( "The Hidden Physics Of RNA-LNPs: Tuning RNA Encapsulation For Potency And Safety")
The Hidden Physics Of RNA-LNPs: Tuning RNA Encapsulation For Potency And SafetyWhy LNPs that look identical behave differently in cells. This piece reveals how mixing physics and payload uniformity shape RNA potency, safety, dosing, and manufacturability—beyond size alone.
-
![data business analysis, Data Management System, metrics-GettyImages-1480239160]( "Benchmarking RNA Delivery Performance: Toward Standardized Metrics For Translational Success")
Benchmarking RNA Delivery Performance: Toward Standardized Metrics For Translational SuccessAs RNA pipelines mature, delivery success demands shared benchmarks. This article proposes standardized, stage-specific metrics to compare platforms, guide optimization, and strengthen regulatory confidence.
FORMULATION VIDEOS
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their thoughts on the scientific-research and CMC-related reasons that have made the lipid nanoparticle the “darling” of the delivery world for mRNA/RNA products today.
Three LNP experts from Sanofi, Hopewell Therapeutics, and BioNTech collectively discuss how far we’ve come in understanding the structure of our LNPs while also shedding light on the variables that have the greatest potential of causing shifts in our products’ structure/function.
Explore a structured approach to optimizing and scaling plasmid DNA production using E. coli, with insights into key growth parameters, benchtop feasibility, and pilot-scale performance.
There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-96310150-microfluidics.jpg]( "Accelerated Development Of Self-Amplifying mRNA (saRNA) Vaccines Using Microfluidics")
We showcased the utility of microfluidics to enable low shear, rapid screening of preclinical candidates and the swift advancement to GMP-enabling studies.
-
![GettyImages-2151198847-lipid-nanoparticle-with-rna-strands]( "Advancing Cell Therapies With Lipid Nanoparticles")
Cell therapies, using reprogrammed immune cells, offer innovative treatments for diseases. Discover how lipid nanoparticles (LNPs) enhance these therapies by delivering RNA for gene modulation and next-gen treatments.
-
![Worker Holding Vaccine Vial GettyImages-1403976499]( "Potent Immune Response With Vernal's LNP-mRNAs")
As mRNA medicine continues to evolve, understand how trusted manufacturing partners will continue to play a pivotal role in translating innovative concepts into clinical reality.
-
![GettyImages-1305685152 vaccine]( "The Heroes Of Vaccine Development: Lipid Nanoparticles")
Lipid nanoparticles (LNPs) have played a crucial role in COVID-19 vaccine development as efficient mRNA delivery systems, exhibiting versatility and effectiveness in accelerating the process.
-
![GettyImages-950086574 drug development]( "Recommendations For Successful IND Approval Of RNA-LNP Drugs")
The existing regulatory system is ambiguous for RNA therapeutics. Leverage this Investigational New Drug (IND) guide to help accelerate and strengthen the process IND filing of novel nanomedicines.
-
![Medical scientists analyzing research-GettyImages-1413600685]( "Developing A Comprehensive Regulatory Approach For LNP Drugs")
The path to regulatory approval for LNPs demands carefully considered strategies. By adopting proactive and strategic approaches, developers can overcome regulatory hurdles on the path to approval.
-
![Lipid Nanoparticles GettyImages-1437855772]( "Advancing RNA-LNP Therapeutics As An Alternative To Viral Vectors")
RNA-LNP therapeutics offer a flexible, transient alternative to traditional viral vectors for genetic medicine. Learn about the advantages of LNPs in safety, scalability, and payload versatility.
